Growth In The Familial Amyloid Polyneuropathy Market Is Being Driven By Growth Of The Driven By Rising Surgical Procedures
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Size Of The Familial Amyloid Polyneuropathy Market Expected To Scale Between 2026 And 2030?
The familial amyloid polyneuropathy market has experienced robust growth in recent times. This market is projected to expand from $1.65 billion in 2025 to $1.79 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.3%. Historically, this expansion has been driven by factors such as enhanced rare disease diagnosis, increased genetic disorder awareness, advancements in transplant medicine, ongoing neurology research, and the widespread adoption of supportive care.
The market for familial amyloid polyneuropathy is anticipated to experience substantial expansion over the upcoming years. This market is projected to reach a valuation of $2.43 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 8.0%. Several factors are expected to drive this growth throughout the forecast period, including advancements in gene therapy, increased early genetic testing, dedicated funding for rare diseases, wider adoption of precision medicine, and the expansion of specialty pharmacies. Key trends anticipated during the same period encompass the rising acceptance of TTR stabilizers, the proliferation of gene silencing therapies, heightened genetic screening efforts, an intensified focus on treating rare diseases, and the establishment of more specialty care centers.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24532&type=smp
What Leading Drivers Are Supporting The Familial Amyloid Polyneuropathy Market Expansion?
An increasing emphasis on gene therapy is projected to drive the future expansion of the familial amyloid polyneuropathy market. Gene therapy is a treatment method that modifies or replaces defective genes to address the underlying cause of diseases. It is gaining traction because it targets and repairs faulty genes, offering lasting or permanent cures rather than mere symptom relief. For familial amyloid polyneuropathy, gene therapy focuses on correcting or silencing the defective transthyretin (TTR) gene to prevent harmful amyloid protein formation. This helps reduce amyloid deposits, thereby slowing disease progression and preserving nerve function. For instance, in July 2023, according to the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, there were 247 gene therapies in Phase II at the end of the first quarter of 2023, a number that rose by 5% to reach 260 by the end of the second quarter. Therefore, the heightened focus on gene therapy is propelling the growth of the familial amyloid polyneuropathy market.
Which Segments Define The Familial Amyloid Polyneuropathy Market Segment Structure?
The familial amyloid polyneuropathy market covered in this report is segmented –
1) By Treatment: Medication, Gene Therapy, Supportive Care, Pain Management, Symptomatic Treatment
2) By Diagnosis: Genetic Testing, Biopsy, Imaging, Other Diagnosis
3) By Patient Age Group: Pediatric, Adult, Geriatric
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies, Direct Sales
5) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users
Subsegments:
1) By Medication: Transthyretin (TTR) Stabilizers, Transthyretin (TTR) Gene Silencers, Tafamidis, Diflunisal, Patisiran
2) By Gene Therapy: Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or Cas9-Based Therapy, RNA Interference (RNAi) Therapy, Antisense Oligonucleotides (ASO) Therapy
3) By Supportive Care: Physical Therapy, Occupational Therapy, Nutritional Support, Psychological Counseling
4) By Pain Management: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Opioids, Antidepressants, Anticonvulsants
5) By Symptomatic Treatment: Gastrointestinal Symptom Management, Cardiovascular Symptom Management, Autonomic Dysfunction Management, Orthostatic Hypotension Treatment
What Emerging Trends Are Seen In The Familial Amyloid Polyneuropathy Market?
Leading companies in the familial amyloid polyneuropathy market are concentrating on developing advanced treatment solutions, such as RNA interference (RNAi) therapeutics, to slow disease progression and enhance patient outcomes. These RNA interference (RNAi) therapeutics are sophisticated treatments that silence disease-causing genes by targeting their messenger RNA (mRNA). This strategy prevents the production of harmful proteins, thereby addressing genetic diseases at their fundamental origin. For example, in March 2025, Alnylam Pharmaceuticals, a US-based biopharmaceutical company, introduced AMVUTTRA (vutrisiran), which obtained approval from the Food and Drug Administration (FDA) for managing cardiomyopathy stemming from wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. It is administered as four subcutaneous doses per year and is designed to treat both ATTR-CM and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN). By reducing the production of the transthyretin (TTR) protein, which is the underlying cause of the disease, it significantly decreases cardiovascular mortality, hospitalizations, and urgent heart failure visits, as evidenced in the HELIOS-B Phase 3 clinical trial.
Who Are The Established Players Within The Familial Amyloid Polyneuropathy Market?
Major companies operating in the familial amyloid polyneuropathy market are Pfizer Inc., AstraZeneca plc, Novo Nordisk A/S, Regeneron Pharmaceuticals Inc., NYU Langone Hospitals, Alexion Pharmaceuticals Inc., Mount Sinai Medical Center, PTC Therapeutics Inc., Mayo Foundation for Medical Education and Research, Arcturus Therapeutics Inc., Precision BioSciences Inc., Creative Biolabs, Stanford Health Care, Duke University Health System, YolTech Therapeutics
Get The Full Familial Amyloid Polyneuropathy Market Report:
Which Region Represents The Largest Share Of The Familial Amyloid Polyneuropathy Market?
North America was the largest region in the familial amyloid polyneuropathy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the familial amyloid polyneuropathy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Familial Amyloid Polyneuropathy Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Familial Amyloid Polyneuropathy Market 2026, By The Business Research Company
Peripheral Neuropathy Market Report 2026
https://www.thebusinessresearchcompany.com/report/peripheral-neuropathy-global-market-report
Transthyretin Amyloidosis Treatment Market Report 2026
Diabetic Neuropathy Market Report 2026
https://www.thebusinessresearchcompany.com/report/diabetic-neuropathy-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
